AV Remdesivir

Aktuelle Version vom 11. April 2021, 09:25 Uhr

drug: Remdesivir, GS-5734; metabolites: GS-441524, Captisol, GS-704277 prodrug: GS-441524

• one hospital on...

32223926 2020. Remdesivir attenuates high fat diet (HFD)-induced NAFLD by regulating hepatocyte dyslipidemia and inflammation via the suppression of STING
32283108 ä. Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
32020029 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
32378648 2020. Rapid review for the anti-coronavirus effect of remdesivir
32147516 ä. Arguments in favour of remdesivir for treating SARS-CoV-2 infections
32333086 ä. Remdesivir bei Patienten mit schwerer COVID-19
32361744 ä. Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease
32275812 ä. Compassionate Use of Remdesivir for Patients with Severe Covid-19
32284326 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
32094225 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
32258351 2020. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
32054787 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
32239125 2020. Remdesivir, la esperanza antiviral frente al SARS-CoV-2
32358203 ä. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
32145386 ä. Remdesivir as a possible therapeutic option for the COVID-19
32247927 ä. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
32321732 2020. Remdesivir in covid-19
32357949 2020. Covid-19: Remdesivir is helpful but not a wonder drug, say researchers
32350436 2020. Hopes rise for coronavirus drug remdesivir
32483554 ä. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
32281114 2020. Delayed Initiation of Remdesivir in a COVID-19-Positive Patient
32401466 2006. Remdesivir
32456606 2020. Synergistic effect of vitamin D and remdesivir can fight COVID-19.
32503874 2020. Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.
32458279 2020. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
32396771 2020. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary.
32397906 2020. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.
32439198 2020. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.
32513665 2020. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.
32418190 2020. Early experience with remdesivir in SARS-CoV-2 pneumonia.
32521159 2020. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
32468196 2020. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
32515337 2020. [Remdesivir til behandling af COVID-19-pneumoni].
32445440 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32516797 2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
32572516 2020. Remdesivir bei Patienten mit COVID-19.
32589775 2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.

32568620 2020. Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease - in silico approach.
32407959 2020. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
32412709 2020. Compassionate Use of Remdesivir in Covid-19. Reply.
32412708 2020. Compassionate Use of Remdesivir in Covid-19.
32412707 2020. Compassionate Use of Remdesivir in Covid-19.
32412706 2020. Compassionate Use of Remdesivir in Covid-19.
32412705 2020. Compassionate Use of Remdesivir in Covid-19.
32554811 2020. Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir.
32506110 2020. Use of Remdesivir in the Management of COVID-19: A Systematic Review on Current Evidences.
32459919 2020. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
32446287 2020. Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.
32492200 2020. Remdesivir and Tocilizumab: Mix or Match.
32423584 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
32423580 2020. Remdesivir for COVID-19: challenges of underpowered studies
32573468 2020. Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.

32607555 2020. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
32568289 2020. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
32595613 2020. Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition.
32520466 2020. Remdesivir et Covid-19: resultats negatifs mais methode de recherche (enfin) appropriee !
32574236 2020. Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
32579980 2020. Validity of the UK Early Access to Medicines Scheme Criteria for Remdesivir use in patients with COVID-19 disease.
32562915 2020. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
32594120 2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.
32402130 2020. What Do We Know About Remdesivir Drug Interactions?
32405143 2020. Remdesivir - A giant step, or a tiptoe?
32459913 2020. Remdesivir - An Important First Step.
32550880 2020. Recommandations EMA sur l'usage compassionnel du remdesivir.
32579163 2020. Missed Opportunities on Emergency Remdesivir Use.
32618794 2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
32619764 2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.
32649074 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649075 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649076 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649077 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649078 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
32651941 2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.
32651941 2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.
32652563 2020. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
32665225 2020. Covid-19: Experts criticise claim that remdesivir cuts death rates.
32665809 ?. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
32665809 2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
32668216 2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
32670785 2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.
32687756 2020. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
32696862 2020. Use of remdesivir for patients with Covid-19: a review article.
32702095 2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
32702590 2020. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.
32706859 2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.
32711596 2020. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
32721580 2020. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.
32725454 2020. Liver injury in remdesivir-treated COVID-19 patients.
32726230 2020. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
32726231 2020. Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19.
32732277 2020. Covid-19: Remdesivir probably reduces recovery time, but evidence is uncertain, panel finds.
32732352 2020. Remdesivir for severe covid-19: a clinical practice guideline.
32735655 2020. The Multidimensional Challenge of Treating COVID-19: Remdesivir is a Foot in the Door.
32753375 2020. BET 1: The role of remdesivir in COVID-19 infection.
32757500 2020. Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series.
32763313 2020. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.
32771381 2020. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019.
32773440 2020. A Review of Remdesivir for COVID-19: Data to Date.
32786401 2020. A Chemoenzymatic Synthesis of the (RP)-Isomer of the Antiviral Prodrug Remdesivir.
32792942 2020. Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of I K(M) or I K(DR) and in the Stimulation of I MEP.
32804187 2020. Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.
32813283 2020. Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis.
32827627 2020. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
32814341 2020. COVID-19 and remdesivir in pediatric patients: the invisible part of the iceberg.
32821086 2020. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
32821882 2020. Metabolic Efficacy of Phosphate Prodrugs and the Remdesivir Paradigm.
32821934 2020. Efficacy of Remdesivir in COVID-19.
32821939 2020. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
32829390 2020. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.
32838064 2020. Remdesivir and its antiviral activity against COVID-19: A systematic review.
32861965 2020. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
32863273 2020. Antiviral treatment for COVID-19: the evidence supporting remdesivir.
32864571 2020. Potential Interactions of Remdesivir with Pulmonary Drugs: a Covid-19 Perspective.
32868327 2020. Removal of remdesivir's metabolite GS-441524 by hemodialysis in a double lung transplant recipient with COVID-19.
32870481 2020. Remdesivir: First Approval.
32870563 2020. Catalytic Asymmetric Synthesis of the Anti-COVID-19 Drug Remdesivir.
32874008 2020. Indian perspective of remdesivir: A promising COVID-19 drug.
32882638 2020. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
32896184 2020. Remdesivir, a remedy or a ripple in severe COVID-19?
32909843 2020. Remdesivir emergency approvals: a comparison of the U.S., Japanese, and EU systems.
32921965 2020. Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.
32934969 2020. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion.
32942923 2020. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
32944838 2020. Pulmonary administration of remdesivir in the treatment of COVID-19.
32963442 2020. Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times.
32967965 2020. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action.
32968487 2020. The use of remdesivir outside of clinical trials during the COVID-19 pandemic.
32986807 2020. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19.
32988821 2020. Captisol and GS-704277, but not GS-441524, are credible mediators of remdesivir's nephrotoxicity.
33006138 2020. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.
33009111 2020. A Potential Antiviral Treatment for COVID-19: Remdesivir.
33009120 2020. A Potential Antiviral Treatment for COVID-19: Remdesivir.
33010830 2020. Remdesivir and COVID-19.
33010831 2020. Remdesivir and COVID-19.
33010832 2020. Remdesivir and COVID-19.
33010833 2020. Remdesivir and COVID-19.
33010835 2020. Remdesivir and COVID-19 - Authors' reply.
33011825 2020. Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19.
33015819 2020. Remdesivir-COVID-19: drug interactions in dentistry.
33015938 2020. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
33017170 2020. Remdesivir for Adults With COVID-19 : A Living Systematic Review for an American College of Physicians Practice Points.
33017175 2020. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
33028676 2020. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases.
33031500 2020. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19.
33031623 2020. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
33041326 2020. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice.
33043163 2020. Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven.
33055231 2020. Remdesivir against COVID-19 and Other Viral Diseases.
33060041 2020. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
33065096 2020. Computational and theoretical exploration for clinical suitability of Remdesivir drug to SARS-CoV-2.
33068241 2020. Remdesivir and COVID-19.
33077424 2020. Covid-19: Remdesivir has little or no impact on survival, WHO trial shows.
33085408 2020. Remdesivir
33085486 2020. Cyanoamidine Cyclization Approach to Remdesivir's Nucleobase.
33088576 2020. Critical reappraisal of remdesivir investigational trials in COVID-19.
33091434 2020. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
33093748 2020. Remdesivir for COVID-19.
33100032 2020. Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV.
33103195 2020. Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19.
33105618 2020. Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing.
33109039 2020. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
33117850 2020. Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.
33118617 2020. Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials.
33121991 2020. Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
33124007 2020. Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment.
33124786 2020. Nucleotide analogues as inhibitors of SARS-CoV Polymerase.
33128490 2020. Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.
33130588 2020. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection.
33136164 2020. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
33139290 2020. New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19.
33139967 2020. Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries.
33163977 2020. Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.
33179852 2020. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection.
33185784 2020. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
33190493 2020. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
33200304 2020. Compassionate use of remdesivir in children with COVID-19.
33204761 2020. Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19.
33206336 2020. Remdesivir versus ritonavir/lopinavir in COVID-19 patients.
33208020 2020. CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.
33210457 2020. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
33211457 2012. Remdesivir
33214186 2020. Covid-19: What now for remdesivir?
33229331 2020. Remdesivir for severe covid-19: a clinical practice guideline.
33229428 2020. A Valid Warning or Clinical Lore: An Evaluation of Safety Outcomes of Remdesivir in Patients with Impaired Renal Function from a Multicenter Matched Cohort.
33229429 2020. Off-target In Vitro Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.
33231938 2020. Is remdesivir important in clinical practice as a treatment against COVID19? A study based on metaanalysis data.
33234758 2020. Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia.
33240723 2020. Cardiac Adverse Events With Remdesivir in COVID-19 Infection.
33245577 2020. Clinical studies assessing the efficacy, effectiveness, and safety of remdesivir in management of COVID-19: a scoping review.
33248473 2020. The place for remdesivir in COVID-19 treatment.
33251541 2020. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis.
33252992 2020. Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications.
33260103 2020. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2.
33263094 2020. Remdesivir in patients with estimated glomerular filtration rate < 30mL/min/1.73m(2) or on renal replacement therapy.
33264025 2020. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
33267759 2020. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
33280995 2020. Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS.
33283177 2020. Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase.
33289021 2020. A survey of US hospitals' criteria for the allocation of remdesivir to treat COVID-19.
33296558 2020. A Mechanism-based Pharmacokinetic Model of Remdesivir Leveraging Interspecies Scaling to Simulate COVID-19 Treatment in Humans.
C7229886 ?. Data Monitoring for the Chinese Clinical Trials of Remdesivir in Treating Patients with COVID-19 During the Pandemic Crisis.
C7276122 ?. Remdesivir investigational trials in COVID-19: a critical reappraisal.
C7291615 2020. Remdesivir wohl wirksam bei COVID-19.
C7294886 ?. Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir.
C7314679 ?. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.
C7317081 2020. New potential interaction with emergency COVID-19 medicine remdesivir.
C7348117 2020. Remdesivir: Various toxicities: 4 case reports.
C7677433 2020. Lopinavir/ritonavir/remdesivir: Drug induced liver injury and off label use: 5 case reports.
C7726273 2020. Remdesivir: Intrahepatic cholestasis of pregnancy following compassionate use of remdesivir: case report.
32441826 2020. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.